From: Prevalence of Mycobacterium lentiflavum in cystic fibrosis patients, France
Mean | Standard deviation | Limits | |
---|---|---|---|
Age, y | 22.2 | +/−11.4 | [14.6 - 44.1] |
Pedatric/Adults | 3/3 | ||
Male, % | 100 | ||
FEV, % predicted | 67 % | +/−19 % | [46 – 93 %] |
BMI, kg/m2 | 20 | +/−1.9 | [17.2 – 22.4] |
Infected (met ATS criteria)a | 2/6 | ||
Diabetes | 3/6 | ||
Exocrine pancreatic disease | 6/6 | ||
Pseudomonas aeruginosa | 5/6 | ||
Stenotrophomonas maltophilia | 4/6 | ||
Previous NTM isolationb | 2/6 | ||
MS Staphylococcus aureus | 6/6 | ||
Aspergillus sp. | 5/6 | ||
Other co-infectionc | 4/6 | ||
Azithromycin prophylaxisd | 6/6 | ||
Lung transplanted after isolation | 1/6 |